Clinical Trial Update: Study of Darifenacin in Patients Suffering From Multiple Sclerosis and Neurogenic Detrusor Overactivity [Phase 2]

View source ↗

Summary

Phase 2 study of darifenacin in patients with multiple sclerosis and neurogenic detrusor overactivity was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis
• Neurogenic Detrusor Overactivity

Drugs mentioned

• Darifenacin (darifenacin)

Snippet

Sponsor: Bayer | Conditions: Multiple Sclerosis, Overactive Detrusor | Phase 2 | Status: TERMINATED